Background
==========

Schizophrenia is a disorder characterised by positive symptoms (hallucinations and delusions), thought disorder and negative symptoms (such as apathy). Brain imaging studies have identified structural changes both early in the presentation of the illness and more extensive changes later in the course of the illness \[[@B1]\]. The distribution of changes has been replicated between studies \[[@B2]\], and may be considered a 'structural signature' of schizophrenia within the brain. However, an adequate explanation for this spatial distribution remains elusive. Models have been proposed involving genetic factors coding neuro-protein variants resulting in abnormal development of limbic and frontal-temporal-subcortical networks \[[@B3]\]. However, it remains uncertain which neuro-chemical pathways are responsible and how they cause the spatial changes.

FTLD is characterised by declines in social function, interpersonal conduct, emotional blunting, speech and language abnormalities and loss of insight \[[@B4]\]. It is associated with degeneration of the prefrontal and anterior temporal cortices \[[@B5]\]. However, the topographical distribution of structural brain changes is heterogeneous amongst different patient groups, reflecting behavioral and pathological variants. Although the most common histological feature is tauopathy \[[@B6]\], over half of all patients, including those with a family history of the condition, have no abnormality in the tau gene or protein \[[@B7]\], consistent with pathological and aetiological heterogeneity.

In this study, we investigate whether there is overlap in the distribution of brain changes in First Episode Schizophrenia (FES) and Fronto-Temporal Lobar Degeneration (FTLD). There is evidence for similarities in clinical, neuropsychological and neuroimaging findings in patients with FTLD and schizophrenia \[[@B8]\]. In some cases, patients with FTLD have been diagnosed with a schizophrenia-like psychotic illness years before the dementia diagnosis is made \[[@B9]\]. Echopraxia, echolalia, aprosody of speech, utilisation behavior, 'negative' symptoms, self-neglect, and bizarre, compulsive, and stereotyped behaviors are well recognised in both disorders. Executive dysfunction with relative preservation of visual perception and spatial skills \[[@B7],[@B10]\] and deficits in social cognition, theory of mind, empathy and affect recognition have been identified in both disorders \[[@B11]\].

Frontal, temporal and hippocampal atrophy \[[@B12],[@B13]\] and regionally specific reductions in the anterior corpus callosum \[[@B14],[@B15]\] and anterior hippocampus \[[@B16],[@B17]\] have been described in MRI studies of both FTLD and schizophrenia. Frontal hypoperfusion on single photon emission tomography or positron emission tomography constitutes one of the imaging criteria for the diagnosis of frontotemporal dementia \[[@B18]\], and is also one of the most robust functional imaging findings in the schizophrenia literature in patients with chronic and first-episode illness \[[@B19]\]. There is also recent evidence that schizophrenia and FTLD co-occur in some families, suggesting the possibility of a common vulnerability to these disorders \[[@B20]\]. While the pathology of schizophrenia remains uncertain, there have been considerable advances in elucidating the complex and heterogeneous pathology of FTLD \[[@B21],[@B22]\]. We have chosen to examine FES rather than chronic schizophrenia because the structural changes in FES may more accurately reflect the pathological changes of the disorder, and may minimize the confounding effects of long-term medication and other aspects of chronic illness. Different antipsychotics have individual volumetric effects on brain structure \[[@B23],[@B24]\] and therefore, patients with FES were used in order to reduce heterogeneity.

The aim of this review is to determine the distribution of brain changes in FTLD and FES, by employing an established meta-analytic technique (anatomical likelihood estimation, ALE) \[[@B25]\] that is widely used for coordinate-based meta-analyses of neuroimaging data by converting the co-ordinates of peak gray matter changes from multiple published studies into spatial probability maps. However, the accuracy and extent of these maps is dependent on the total number of peak co-ordinates available from published studies. Therefore, this study employs a new statistical approach to investigate the degree of spatial correspondence between the two disorders, taking into account the greater availability of data co-ordinates for FTLD than FES. The comparison of brain changes between an individual MRI scan and maps for different disorders may become increasingly important for early diagnosis, as currently, diagnoses of psychiatric disorders are made on the basis of clinical manifestations and associated psychosocial disturbances. There are current initiatives to encourage the classification of mental disorders for research purposes, such as the RDoC (Research Domain Criteria) approach \[[@B26]\]. Several MRI-based studies have attempted to distinguish between patients and healthy subjects with high accuracy (ranging from 75 to 92%) \[[@B27]\]. Therefore, the statistical technique described in this paper for assessing spatial overlap may have wider clinical utility in the future.

Methods
=======

The PRISMA (preferred reporting items for systematic reviews and meta-analyses) guidelines were followed to conduct this review \[[@B28]\].

Literature search
-----------------

A comprehensive keyword search of EMBASE (from 1980), PsycINFO (from 1801) and Medline (from 1950), was conducted using the following search strategy. The following Boolean phrase was used: {(\[Magnetic Resonance Imaging\] OR \[MRI\]) AND (\[Schizophrenia\] OR \[schizo\*\] OR \[FTLD\] OR \[Fronto-Temporal Lobar Degeneration) AND (\[Voxel\] OR \[VBM\])}. Both free-text and expanded medical subject headings were be used. The search strategy was supplemented using a cited reference search, and by inspecting the reference lists of included articles. The search was conducted in January 2011. No time span was specified for date of publication.

Criteria for inclusion/exclusion
--------------------------------

Studies were considered for the review using the following inclusion criteria: 1) they were published in English as a peer-reviewed article (rather than a letter, abstract, or case report); 2) they compared a sample of formally diagnosed subjects with a group of unrelated healthy control subjects; 3) they utilized voxel-based analysis of gray matter in structural MRI scans to investigate differences in whole-brain; and 4) they reported the three-dimensional co-ordinates of changes in stereotactic space.

FTLD studies were considered if they consisted of subjects with Fronto-Temporal Lobar Degeneration or related diagnoses, such as Semantic Dementia. FES studies were considered if they included a group of subjects with schizophrenia or related diagnoses, specifically first episode schizoaffective disorder or psychosis. Only first-episode schizophrenia patients were included, therefore, papers must have documented that patients were experiencing symptoms related to psychosis without a prior diagnosis without administration of prior antipsychotic medication in order to be included in our meta-analysis.

Studies were excluded if: 1) there were insufficient data to extract the number of subjects in each group; 2) there were fewer than five subjects in either the patient group or the comparison group; 3) the comparison groups consisted of patients with minor non-psychiatric illnesses; 4) the patient group in the schizophrenia studies consisted of subjects with child-onset schizophrenia or chronic schizophrenia beyond the stage of first-episode psychosis; 5) the studies used region-of-interest volumetric analyses, or the deformation- or tensor-based volumetric methods for measuring regional brain volumes; and 6) the data contributed to another publication, in which case the publication with the largest group size under study was selected.

Data abstraction
----------------

Data were extracted from two independent investigators (BO and IEW) and were double-checked. Information gathered from the studies included the authors, year of publication, demographic variables (number of subjects, age at baseline and gender), illness variables (diagnosis and duration of illness), and the reported stereotactic coordinates related to the comparisons between structural MRI scans of patients and controls from every selected study. Co-ordinates that were reported in the stereotactic space of the Montreal Neurological Institute (MNI) were converted to Talairach coordinates using the Lancaster transform (icbm2tal) in the GingerALE 2.0 program \[[@B29]\]. Talairach co-ordinates that had been generated by the Brett transform applied to statistical parametric mapping MNI co-ordinates were transformed back to MNI space in GingerALE and then to Talairach space using the Lancaster transform.

Statistical analysis
--------------------

Meta-analyses were performed using the Talairach stereotactic coordinates derived from the included studies. Meta-analyses were carried out using GingerALE 2.0 \[[@B29]\]. This uses the technique of Activation Likelihood Estimation (ALE) \[[@B25]\] and permits weighting of studies in the meta-analysis, e.g. based on sample size. This modification of ALE treats the spatial conjunction of co-ordinates from separate studies as more significant than conjunction of co-ordinates from a single study. The probability values can then be interpreted on an image-wide basis after correction for multiple testing using the False Discovery Rate, a method which controls the proportion of type 1 errors (false positives) among significant results \[[@B30]\].

Descriptive meta-analyses were then performed to identify the distribution of brain changes in FES and FTLD, when compared to control subjects. The overlap of these two distributions was measured.

Spatial overlap testing
-----------------------

We tested the overlap of the FTLD co-ordinates with the FES spatial map generated by ALE using a randomisation method based on our previous work hybridising ALE spatial techniques with GSMA (Genome Scan Meta-Analysis) statistical methods \[[@B31]\].

For each FTLD study, the reported loci of maximal anatomical difference were modeled as the peaks of three-dimensional Gaussian probability density functions with full-width half-maximum of 7 mm, within a brain mask of size N of linear dimension 2 mm. The voxels in this probability image were then ranked from N (highest probability) to 1 (lowest probability), giving voxels of equal probability a mean rank. This created a rank image for each study which was smoothed with a 7 mm Gaussian filter. This image was masked with the First Episode Schizophrenia spatial map generated by ALE and the total value of ranks within the mask was calculated. The total for all studies of ranks within the mask was calculated ('FES Mask Total').

A null distribution for the FES Mask Total result was derived by 1000 permutations of the same process, but using an equal number of co-ordinates for each study derived from a random uniform distribution of coordinates within the brain mask. The probability of a FES Mask Total under the null hypothesis was calculated as the proportion of permutations giving a value equal or greater than the actual value.

The data set being tested was included in the ranking of all known outcomes. The significance threshold was set at p \< 0.05.

Results
=======

The electronic literature search of the three databases yielded 396 articles, of which 181 were retrieved in full-text format. 56 studies were identified as being potentially appropriate to be included in the meta-analysis, and the inclusion and exclusion criteria was used throughout the selection process to yield 38 articles appropriate for use in the meta-analysis. Figure [1](#F1){ref-type="fig"} displays a flow diagram that shows the reasons for exclusion at each stage of the selection process.

![Study flow and reasons for exclusion.](1471-244X-12-104-1){#F1}

A total of eighteen FES studies and twenty FTLD studies were identified for inclusion in the meta-analysis (Table [1](#T1){ref-type="table"}), having published MRI co-ordinates of gray matter changes in FES or FTLD patients and healthy controls \[[@B32]-[@B69]\]. The FES studies included a total of 555 patients and 621 comparison subjects, and the FTLD studies included a total of 311 patients and 431 comparison subjects. Among the FES patient group, the smallest size sample was 13 schizophrenia patients \[[@B44]\], and the largest size sample was 68 schizophrenia patients \[[@B40]\]. Among the FTLD patient group, the smallest size sample was 6 patients \[[@B50],[@B62]\], and the largest size sample was 51 patients \[[@B60]\]. All included studies were published from 2000 to 2010.

###### 

Studies included in the Meta-analyses

  **First author, Year of publication**    **Disorder type**                 **Number of patients**   **Number of controls**   **Mean age of patients (yrs)**   **Mean age of controls (yrs)**
  ---------------------------------------- --------------------------------- ------------------------ ------------------------ -------------------------------- --------------------------------
  **FIRST EPISODE SCHIZOPHRENIA**                                                                                                                               
    Berge, 2010 \[[@B32]\]                 PNOS (FE)                         21                       20                       24.8                             25.3
    Chua, 2007 \[[@B33]\]                  SZ, SZF, BPSY (FE)                26                       38                       32.0                             33.0
    Douaud, 2007 \[[@B34]\]                SZ (FE)                           25                       25                       16.5                             16.2
    Ebdrup, 2010 \[[@B35]\]                SZ (FE)                           38                       43                       26.2                             26.9
    Jayakumar, 2005 \[[@B36]\]             SZ (FE)                           18                       18                       24.9                             25.7
    Job, 2002 \[[@B37]\]                   SZ (FE)                           34                       36                       21.4                             21.2
    Kasparak, 2007 \[[@B38]\]              SZ (FE)                           22                       18                       23.7                             24.1
    Kubicki, 2002 \[[@B39]\]               SZ (FE)                           16                       18                       26.0                             24.0
    Lui, 2009 \[[@B40]\]                   SZ (FE)                           68                       68                       24.2                             24.7
    Meda, 2008 \[[@B41]\]                  WPIC                              22                       21                       25.1                             26.2
    Molina, 2010 \[[@B42]\]                SZ (FE)                           30                       41                       25.8                             29.4
    Price, 2010 \[[@B43]\]                 SCZ, SZA (FE)                     48                       47                       26.2                             24.8
    Salgado-Pineda, 2003 \[[@B44]\]        SZ (FE)                           13                       13                       23.8                             23.4
    Schaufelberger, 2007 \[[@B45]\]        SZ, SZF (FE)                      62                       94                       27.6                             30.2
    Venkatasubramanian, 2010 \[[@B46]\]    SZ (FE)                           30                       27                       30.1                             27.4
    Whitford, 2005 \[[@B47]\]              SZ (FES)                          41                       47                       19.8                             19.3
    Witthaus, 2009 \[[@B48]\]              SZ (FES)                          23                       29                       26.4                             25.7
    Yoshihara, 2008 \[[@B49]\]             SZ (FES)                          18                       18                       15.8                             15.8
  **Total (mean)**                                                           **555 (30.8)**           **621 (34.5)**           **(24.4)**                       **(24.5)**
  **FRONTO-TEMPORAL LOBAR DEGENERATION**                                                                                                                        
    Adlam, 2006 \[[@B50]\]                 FTLD: SD, fPPA                    6                        12                       62.8                             65.0
    Boccardi, 2005 \[[@B51]\]              FTLD                              9                        26                       62.0                             69.0
    Boxer, 2003 \[[@B52]\]                 FTLD: SD                          11                       15                       66.2                             69.6
    Chang, 2005 \[[@B53]\]                 FTLD: FTLD&ALS vs. ALS            10                       10                       64.5                             49.9
    Desgranges, 2007 \[[@B54]\]            FTLD: SD                          10                       17                       65.7                             65.8
    Gee, 2003 \[[@B55]\]                   FTLD                              29                       12                       65.1                             68.5
    Gorno-Tempini, 2004 \[[@B56]\]         FTLD: SD                          10                       10                       63.0                             69.1
    Grossman, 2004 \[[@B57]\]              FTLD                              29                       12                       65.1                             68.5
    Kanda, 2008 \[[@B58]\]                 FTLD: bvFTD                       13                       20                       64.9                             65.2
    Kim, 2007 \[[@B59]\]                   FTLD                              14                       61                       63.3                             68.0
    Libon 2009 \[[@B60]\]                  FTLD: bvFTD                       51                       43                       61.3                             n/av: age-matched
    Massimo 2009 \[[@B61]\]                FTLD: disinhibition-predominant   4                        10                       63.6                             64.1
    Mummery 2000 \[[@B62]\]                FTLD: SD                          6                        14                       60.5                             62.0
    Nestor 2003 \[[@B63]\]                 FTLD: PNFA                        7                        10                       71.5                             65.9
    Pardini 2009 \[[@B64]\]                FTLD: bvFTD                       22                       12                       60.3                             n/av: age-matched
    Pereira 2009 \[[@B65]\]                FTLD: ubiquitin positive          9                        25                       64.0                             63.8
    Rabinovici 2007 \[[@B66]\]             FTLD                              18                       40                       62.5                             63.5
    Rosen 2002 \[[@B67]\]                  FTLD: bvFTD                       20                       20                       61.8                             62.3
    Seeley 2008 \[[@B68]\]                 FTLD: bvFTD CDR2-3                15                       45                       62.3                             68.3
    Williams 2005 \[[@B69]\]               FTLD                              18                       17                       60.8                             61.7
  **Total (mean)**                                                           **311 (15.6)**           **431 (21.6)**           **(63.6)**                       **(65.0)**

All studies using voxel-based morphometry of gray matter compared a patient group with a comparison group. Abbreviations: *BPSY*, Brief Psychotic Disorder; *FE*, First episode; *PNOS*, Psychosis not otherwise specified; *SZ*, Schizophrenia; *SZA*, Schizo-affective disorder; *SZF*, Schizophreniform disorder; *WPIC*, Patients from the Western Psychiatric Institute and Clinic at the University of Pittsburgh; *FTLD*, Fronto-temporal Lobar Degeneration; *SD*, Semantic Dementia; *fPPA*, Fluent form of Primary Progressive Aphasia; *ALS*, Amyotrophic Lateral Sclerosis; *bvFTD*, behavioural / dysexecutive subtype of FTLD; *PFNA*, Progressive non-fluent Aphasia; *CDR*, Clinical Dementia Rating (range: 0.5 -- 3); n/av, data not available.

ALE meta-analyses
-----------------

Eighteen FES studies included 185 co-ordinates of gray matter decreases. Meta-analysis of this data identified gray matter decreases in regions including bilateral head of caudate nucleus, bilateral insula, bilateral amygdala/uncus region and bilateral superior temporal region (Figure [2](#F2){ref-type="fig"}).

![**Regions of gray matter change in FES and FTLD subjects.** Regions of gray matter decreases in FES subjects compared with controls (red), regions of gray matter decreases in FTLD subjects compared with controls (yellow), and overlapping regions of gray matter decreases controls (orange), displayed on a brain template. The left side of the image represents the left side of the brain. The Talairach level (z co-ordinate) is given above each horizontal slice.](1471-244X-12-104-2){#F2}

Twenty FTLD studies provided 260 co-ordinates of gray matter decreases. Meta-analysis of this data identified gray matter decreases in regions including bilateral head of caudate nucleus, bilateral insula, bilateral amygdala/uncus region and bilateral superior temporal region (Table [2](#T2){ref-type="table"}, Figure [2](#F2){ref-type="fig"}).

###### 

Regions of gray matter decreases in FES and FTLD subjects compared with controls

                **Cluster**                **Region**  **Talairach coordinates**                     **Value**   **Volume (mm**^**3**^**)**                 
  --------------------------------------- ------------ -------------------------------------------- ----------- ---------------------------- ----- -------- ------
      **FIRST EPISODE SCHIZOPHRENIA**                                                                                                                       
                      1                       R/L      Caudate                                           2                   14                0    0.0046   1624
                                               R       Caudate                                          10                   10               12    0.0017     
                      2                        L       Uncus                                            −18                  −2               −22   0.0031   1272
                                               L       Amygdala                                         −12                  0                −14   0.0028     
                      3                        R       Superior temporal gyrus                          48                  −24               10    0.0019   400
                                               R       Superior temporal gyrus                          48                  −26               16    0.0018     
                      4                        L       Insula                                           −36                  20                6    0.0025   376
                      5                        L       Transverse temporal gyrus                        −46                 −18               10    0.0021   288
                      6                        R       Middle temporal gyrus                            54                  −26               −2    0.0022   272
                      7                        L       Superior temporal gyrus                          −58                 −26               12    0.0021   272
                      8                        L       Superior temporal gyrus                          −56                  2                −4    0.0021   216
                      9                        R       Insula                                           36                   8                10    0.0021   216
                     10                        R       Parietal lobe: Postcentral gyrus                 54                  −20               44    0.0022   216
                     11                        L       Frontal lobe: Middle frontal gyrus               −30                  50                4    0.002    200
                     12                        L       Frontal lobe: Inferior frontal gyrus             −22                  28               −6    0.0018   184
                     13                        L       Parietal lobe: Postcentral gyrus                 −60                 −18               20    0.002    184
                     14                        R       Amygdala / Uncus                                 20                   −4               −22   0.002    168
                     15                        L       Superior temporal gyrus                          −32                  14               −22   0.0019   152
                     16                        L       Inferior temporal gyrus                          −46                 −14               −18   0.002    152
                     17                        L       Cingulate gyrus                                  −8                   −4               38    0.002    152
                     18                        R       Insula / Claustrum                               34                  −14               12    0.0018   136
                     19                        R       Medial frontal gyrus (BA 8)                      14                   34               36    0.0017   136
                     20                        L       Cingulate gyrus                                   0                  −42               38    0.0016   112
                     21                        R       Medial frontal gyrus (BA 6)                       6                   6                48    0.0017   112
   **FRONTO-TEMPORAL LOBE DEGENERATION**                                                                                                                    
                      1                        R       Amygdala / Uncus                                 22                   −4               −20   0.0029   3744
                                               R       Globus Pallidus region                           20                   2                −4    0.0024     
                                               R       Hippocampus / Parahippocampus                    28                  −20               −10   0.0015     
                      2                        L       Amygdala / Parahippocampus                       −22                  −6               −16   0.0027   2336
                                               L       Globus Pallidus region                           −18                  0                −6    0.0025     
                                               L       Uncus                                            −26                  −4               −28   0.002      
                      3                        L       Anterior cingulate                               −2                   10               −4    0.0024   2144
                                               L       Caudate                                          −8                   10               10    0.0022     
                                               L       Caudate                                          −6                   2                14    0.0015     
                      4                        L       Frontal lobe: Medial frontal gyrus (BA 9)        −4                   48               24    0.003    1256
                      5                        L       Frontal lobe: Inferior frontal gyrus             −36                  24                4    0.0022   936
                                               L       Insula                                           −38                  14                0    0.0016     
                      6                        L       Superior temporal gyrus                          −42                  12               −14   0.0021   896
                                               L       Superior temporal gyrus                          −44                  2                −12   0.0018     
                      7                        R       Frontal lobe: Inferior frontal gyrus             42                   16               −12   0.003    880
                      8                        L       Frontal lobe: Middle frontal gyrus               −44                  8                38    0.0032   784
                      9                        R       Frontal lobe: Inferior frontal gyrus             42                   16               12    0.0025   768
                     10                        L       Frontal lobe: Superior frontal gyrus             −22                  60                2    0.0023   704
                                               L       Frontal lobe: Superior frontal gyrus             −24                  56               12    0.0017     
                     11                        R       Cingulate gyrus                                  16                   26               36    0.0025   576
                     12                        R       Insula                                           42                   −6               −4    0.0021   568
                     13                        L       Temporal lobe: fusiform gyrus                    −42                 −30               −18   0.0027   520
                     14                        L       Frontal lobe: Middle frontal gyrus               −22                  18               50    0.0027   496
                     15                        L       Anterior cingulate                               −2                   32               16    0.002    400
                     16                        R       Caudate                                           8                   12               12    0.0024   376
                     17                        R       Middle temporal gyrus                            48                   2                −28   0.0024   312
                     18                        L       Frontal lobe: Inferior frontal gyrus             −40                  52                2    0.0024   232
                     19                        L       Frontal lobe: Middle frontal gyrus               −28                  34               −14   0.002    224
                     20                        L       Insula                                           −42                  2                 0    0.0017   216
                     21                        L       Parietal lobe (BA 7)                             −20                 −46               58    0.0023   216
                     22                        L       Frontal lobe: Medial frontal gyrus (BA 10)        0                   54               −4    0.0018   192
                     23                        R       Superior temporal gyrus                          28                   14               −30   0.0016   176
                     24                        L       Uncus                                            −34                 −16               −34   0.0017   136
                     25                        R       Cerebellum: Anterior lobe                        48                  −36               −28   0.0023   136
                     26                        R       Frontal lobe: Middle frontal gyrus               36                   44                8    0.0017   120
                     27                        R       Uncus                                            28                  −10               −32   0.0016   112

Common changes in FES and FTLD
------------------------------

Gray matter decreases were present in both disorders in regions including bilateral caudate head, left insula and bilateral uncus region (Figure [3](#F3){ref-type="fig"}).

![**Gray matter deficits in FES subjects (red) and FTLD subjects (yellow). Congruent changes in both disorders are shown in orange.** Brain changes are shown in three-dimensional views with brain sections removed (A, B), a sagittal plane (C), an axial plane (D) and a coronal plane (E). The Talairach co-ordinate for each plane is given above each image (C, D, E) (P = posterior, A = anterior, S = superior, L = left).](1471-244X-12-104-3){#F3}

The spatial congruence between the disorders was estimated by percentage overlap. The FTLD map of gray matter decreases comprised 2450 voxels in a brain mask of 201069 voxels. The FES map of gray matter decreases comprised 888 voxels in a brain mask of 201069 voxels. The overlap between the FTLD and FES maps was 124 voxels. Therefore the overlap of FTLD within FES was 14% (compared to an expected overlap of 1.2% if the FTLD map was randomly distributed in the brain mask). The overlap of FES within FTLD was 5% (compared to an expected overlap of 0.4% if the FES mask was randomly distributed in the brain mask). Applying the spatial overlap testing method, the overlap of the FTLD co-ordinates with the FES spatial map generated by ALE was significant (p = 0.001).

Discussion
==========

In this study, we identified overlap in the distribution of brain changes in First Episode Schizophrenia (FES) and Fronto-Temporal Lobar Degeneration (FTLD). We found that the two disorders involved gray matter deficits in common regions (p = 0.001). These included the basal ganglia (bilateral caudate head), paralimbic (left insula) and limbic (bilateral uncus) regions, as shown in Figure [4](#F4){ref-type="fig"}. To our knowledge, this is the first meta-analysis that compares neuro-structural profiles between FES and FTLD. Our study presents a novel method using ALE analyses to derive a statistical test for the chance overlap of the spatial distribution of the two disorders.

![Venn diagram to summarise the distinct and overlapping regions of gray matter deficits found in FES and FTLD.](1471-244X-12-104-4){#F4}

One approach to investigating the spatial distribution of brain changes in schizophrenia involves conceptualising the disorder as affecting several neural sub-systems which are individually affected in other neuro-psychiatric disorders with genetic or syndromal links to schizophrenia. For example, there is evidence that bipolar disorder and schizophrenia share susceptibility genes, and gray matter deficits of bipolar disorder overlap with those of schizophrenia but are more limited to paralimbic regions involved in emotion regulation \[[@B70]-[@B72]\]. Temporal lobe epilepsy is also associated with psychotic episodes with similarities to schizophrenia and is associated with gray matter deficits in limbic regions, overlapping with those of schizophrenia \[[@B73]-[@B75]\]. Autistic spectrum disorders and schizophrenia share gray matter deficits in the limbo-striato-thalamic circuitry \[[@B76]\], possibly reflecting shared genetic \[[@B77],[@B78]\] and environmental \[[@B79]-[@B82]\] risk factors.

Previous results of meta-analyses and structural neuro-imaging studies of FES and FTLD
--------------------------------------------------------------------------------------

These results confirm those of previous meta-analyses of the two disorders, using smaller samples of primary studies. Several previous meta-analyses using 'region-of-interest' analyses have examined gray matter deficits in schizophrenia \[[@B83],[@B84]\], with consistent findings of medial temporal lobe atrophy \[[@B85]-[@B88]\]. Patients with FES also have smaller whole-brain volume, with greater lateral ventricular volume \[[@B89]\]. Frontal \[[@B90],[@B91]\] and temporal \[[@B37]\] volumes have been reported to be smaller at first episode, and basal ganglia are also affected early in the illness \[[@B33],[@B92]\]. The ALE method has also been used to investigate brain structural abnormalities in schizophrenia derived from studies using voxel-based morpometry analyses \[[@B1],[@B93]\]. In a recent meta-analysis by Chan *et al.,* patients with FES had lower gray matter volumes in frontal, temporal, striatal, and cerebellar regions compared with both control subjects and people who are at genetically high-risk of developing schizophrenia \[[@B94]\]. They mapped progressive changes from the high-risk stage to the first-episode stage, clarifying potential markers for disease risk (anterior cingulate and right insula volume reduction) and for disease onset (caudate volume reduction) \[[@B94]\].

In FTLD, a meta-analysis of voxel-based morphometry studies found predominant frontal and temporal lobe involvement, with specific patterns of atrophy in the three clinical subtypes of FTLD, namely, FTD (frontotemporal dementia), SD (semantic dementia) and PNFA (progressive non-fluent aphasia) \[[@B95]\]. Correspondingly, diagnostic criteria for FTLD create a 'triple dissociation' of these subtypes with a high diagnostic accuracy clinically \[[@B96]\]. The clinical characteristics of each subtype of FTLD correspond well with the neuroanatomical deficits found.

Functional significance of implicated regions and symptoms of FES and FTLD
--------------------------------------------------------------------------

The involvement of the basal ganglia (bilateral gray matter decreases in the caudate head in both disorders) agrees with Middleton and Strick's prediction that abnormalities within cortico-striatal circuits may underlie neuropsychiatric symptoms \[[@B97],[@B98]\]. Anatomical studies have revealed discrete connections between the basal ganglia and the cerebral cortex, reciprocally interconnecting a large and diverse set of cortical areas \[[@B99]\]. Dysregulation and abnormal dopaminergic transmission in these loops may contribute to hyperkinetic movements as well as cognitive impairments \[[@B100]-[@B102]\]. Robbins \[[@B103]\] proposed that the heterogeneous range of core symptoms associated with psychosis, appearing to be associated with a range of structural and functional abnormalities, might be explained by a frontal-striatal hypothesis, where an altered balance in the flow of information between through the basal ganglia could explain the seemingly disparate symptoms and characteristics of schizophrenia and psychotic episodes in FTLD. Our results indicate that the basal ganglia loop in particular incorporating the head of the caudate nucleus, are affected by FES and FTLD, which may at least partly explain their shared symptoms.

Our findings reveal that both disorders are characterised by reduced volumes of various paralimbic and limbic structures. Neuroanatomists and cytoarchitectologists have grouped the regions shown to be affected in FES and FTLD, namely the superior temporal gyrus (temporal pole), rostral and caudal anterior cingulate, posterior cingulate, orbital frontal cortex, insula, and parahippocampal regions, into the paralimbic cortex \[[@B104],[@B105]\]. There is documented evidence to support paralimbic dysfunction in various psychiatric disorders, namely psychopathy \[[@B106]\], bipolar disorder \[[@B72]\], psychotic symptoms in depressive disorder \[[@B107]\] and attention deficit hyperactivity disorder \[[@B108]\]. Our results also indicate that both disorders are characterised by reduced caudate size, lesions of which cause impairments in learning, memory \[[@B109]\] and behaviour through the selection of appropriate sub-goals based on an evaluation of action-outcomes \[[@B110]\]. This may reflect the common symptomatology between the two disorders.

Explanation for congruence
--------------------------

Various explanations need to be considered for the overlap in gray matter deficits between the two disorders. Firstly, the result could be due to coincidence. However, we have applied a statistical test to the spatial congruence which suggests that this is highly unlikely (the p value for the null hypothesis of a random distribution of FTLD co-ordinates within the FES spatial map was p = 0.001). Secondly, the symptoms of neuropsychiatric disorders are related to the anatomy of the brain pathology. Therefore, the selection of schizophrenia and FTLD, which share certain symptoms (as described above) may constrain the anatomical findings towards certain brain regions, in the absence of any other more meaningful connection between the neuropathology of the two disorders. The evidence that schizophrenia and FTLD co-occur in some families \[[@B6]\] suggests the possibility of a more fundamental connection between the two disorders. Thirdly, the neuropathology of the two disorders may be (at the neurochemical pathway level) distinct but the common network identified in this study may be 'a final common pathway' in the pathological process of both disorders, or a common reaction to such processes.

Limitations
-----------

There are limitations of this meta-analysis. Firstly, by meta-analysing co-ordinates of maximum change from primary studies there is a loss of spatial information. This reduces the spatial resolution of the results. Secondly, as more primary studies are published the distribution of changes in each disorder may become more extensive as there is improved power to detect changes. Thirdly, there are alternative approaches for investigating spatial overlap of two disorders. For example, Yu *et al.,* used a post-hoc meta-analytic estimation of the extent to which gray matter compares with controls in bipolar disorder and schizophrenia by using a modification of the ALE method \[[@B71]\]. Lastly, the mean age of patients with FES was 24.4 years, whereas in FTLD, the mean age was 63.6 years (Table [1](#T1){ref-type="table"}). There are no validated methods to account for these differences in an ALE meta-analysis, and it is possible that some of the results may have been affected by "normal" structural brain aging processes \[[@B111]\]. Anatomical likelihood estimation analyses are a relatively novel and changing technique, and as time progresses, standardisation of meta-analysis techniques will help researchers evaluate results from different studies more objectively.

Future directions
-----------------

In the future, localized gray matter deficits detected via the above analyses may be combined with those identified in activation studies of cognitive deficits in schizophrenia and FTLD, in order to understand the correlation between functional and structural connectivity in both disorders. For example, the structural MRI gray matter deficits could be used as nodes for a network analysis \[[@B112]\], as can now be done on individual scans \[[@B113]\], which may be utilized to investigate and compare functional connectivity changes in FES and FTLD.

Conclusions
===========

In summary, we reviewed data from 18 FES studies and 20 studies of FTLD that used voxel-based morphometry to identify common structural brain abnormalities. The brain regions found to be significantly affected included gray matter deficits in the bilateral caudate, left insula and bilateral uncus regions. The overlap in distribution of the disorders does not necessarily indicate a fundamental sharing of neurochemical pathology between FES and FTLD. However, we propose that the emerging genetic, pathological and clinical typology of FTLD may provide a model for the deconstruction of subtypes of schizophrenia.
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